Cognition Total Assets from 2010 to 2024

CGTX Stock

USD 0.44 0.02 4.35%

Cognition Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 35 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

35.2 M

Current Value

35 M

Quarterly Volatility

18 M

Credit Downgrade

Yuan Drop

Covid

Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 91.2 K, Interest Expense of 25.6 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.

Check out the analysis of Cognition Therapeutics Correlation against competitors.

For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Latest Cognition Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Cognition Therapeutics over the last few years. Total assets refers to the total amount of Cognition Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cognition Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Cognition Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cognition Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 35.16 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Cognition Total Assets Regression Statistics

	Arithmetic Mean	17,432,044
	Geometric Mean	11,920,584
	Coefficient Of Variation	103.46
	Mean Deviation	14,672,465
	Median	7,459,000
	Standard Deviation	18,034,639
	Sample Variance	325.2T
	Range	52M
	R-Value	0.69
	Mean Square Error	183.2T
	R-Squared	0.48
	Significance	0
	Slope	2,785,213
	Total Sum of Squares	4553.5T

Cognition Total Assets History

	2024	35 M
	2023	35.2 M
	2022	50.4 M
	2021	59.1 M
	2020	7.1 M

Other Fundumenentals of Cognition Therapeutics

Intangibles To Total Assets

Cognition Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Surpluse	Short Long Term Debt
Total Assets		0.98	0.95	0.07	-1.0	-0.78	0.94	0.78	-0.52	-0.95	0.99	1.0	0.91	1.0	0.67	0.91	-0.84	-0.37	-0.38
Total Stockholder Equity	0.98		0.99	0.2	-0.99	-0.87	0.96	0.79	-0.55	-0.99	1.0	0.98	0.95	0.97	0.61	0.95	-0.83	-0.52	-0.52
Net Tangible Assets	0.95	0.99		0.26	-0.96	-0.92	0.96	0.8	-0.6	-1.0	0.99	0.95	0.96	0.93	0.6	0.96	-0.84	-0.62	-0.63
Current Deferred Revenue	0.07	0.2	0.26		-0.08	-0.4	0.11	-0.04	0.23	-0.29	0.18	0.05	0.35	0.01	-0.5	0.35	0.25	-0.38	-0.39
Net Debt	-1.0	-0.99	-0.96	-0.08		0.8	-0.96	-0.77	0.53	0.97	-0.99	-1.0	-0.91	-0.99	-0.65	-0.91	0.84	0.42	0.43
Retained Earnings	-0.78	-0.87	-0.92	-0.4	0.8		-0.8	-0.8	0.7	0.91	-0.87	-0.77	-0.91	-0.74	-0.55	-0.91	0.78	0.82	0.83
Accounts Payable	0.94	0.96	0.96	0.11	-0.96	-0.8		0.73	-0.55	-0.96	0.96	0.95	0.9	0.93	0.59	0.9	-0.82	-0.5	-0.51
Long Term Debt	0.78	0.79	0.8	-0.04	-0.77	-0.8	0.73		-0.88	-0.77	0.8	0.78	0.85	0.76	0.86	0.85	-0.88	-0.42	-0.44
Net Receivables	-0.52	-0.55	-0.6	0.23	0.53	0.7	-0.55	-0.88		0.56	-0.57	-0.53	-0.6	-0.5	-0.88	-0.6	0.86	0.57	0.58
Total Liab	-0.95	-0.99	-1.0	-0.29	0.97	0.91	-0.96	-0.77	0.56		-0.99	-0.95	-0.96	-0.93	-0.57	-0.96	0.81	0.6	0.61
Net Invested Capital	0.99	1.0	0.99	0.18	-0.99	-0.87	0.96	0.8	-0.57	-0.99		0.98	0.95	0.97	0.64	0.95	-0.85	-0.51	-0.52
Total Current Assets	1.0	0.98	0.95	0.05	-1.0	-0.77	0.95	0.78	-0.53	-0.95	0.98		0.91	1.0	0.67	0.91	-0.85	-0.37	-0.38
Capital Stock	0.91	0.95	0.96	0.35	-0.91	-0.91	0.9	0.85	-0.6	-0.96	0.95	0.91		0.88	0.56	1.0	-0.76	-0.52	-0.54
Net Working Capital	1.0	0.97	0.93	0.01	-0.99	-0.74	0.93	0.76	-0.5	-0.93	0.97	1.0	0.88		0.68	0.88	-0.84	-0.34	-0.34
Short Term Debt	0.67	0.61	0.6	-0.5	-0.65	-0.55	0.59	0.86	-0.88	-0.57	0.64	0.67	0.56	0.68		0.56	-0.92	-0.28	-0.28
Common Stock	0.91	0.95	0.96	0.35	-0.91	-0.91	0.9	0.85	-0.6	-0.96	0.95	0.91	1.0	0.88	0.56		-0.76	-0.52	-0.54
Property Plant Equipment	-0.84	-0.83	-0.84	0.25	0.84	0.78	-0.82	-0.88	0.86	0.81	-0.85	-0.85	-0.76	-0.84	-0.92	-0.76		0.54	0.54
Capital Surpluse	-0.37	-0.52	-0.62	-0.38	0.42	0.82	-0.5	-0.42	0.57	0.6	-0.51	-0.37	-0.52	-0.34	-0.28	-0.52	0.54		1.0
Short Long Term Debt	-0.38	-0.52	-0.63	-0.39	0.43	0.83	-0.51	-0.44	0.58	0.61	-0.52	-0.38	-0.54	-0.34	-0.28	-0.54	0.54	1.0

Click cells to compare fundamentals

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	35.2 M	35 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC